Search results
Results From The WOW.Com Content Network
ELIQUIS patient website for: Savings and Coverage. ELIQUIS Free 30-Day Trial activation. ELIQUIS Co-pay Card requests. Rx coverage and reimbursement information. Support and Education. ELIQUIS 360 newsletters and emails. Patient education videos. Patient education/resource downloads.
Welcome to Eliquis.com. If you are visiting from one of the countries below, please click on the respective flag to access your local country website: If you are a healthcare professional based in the US, please CLICK HERE. If you are a patient prescribed apixaban based in the US, please CLICK HERE.
Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and MEDICATION GUIDE. ELIQUIS is available in 2.5 mg and 5 mg tablets. See Indications and Important Safety Information, including Boxed WARNINGS. Learn about ELIQUIS® an oral anticoagulant and its indications.
ELIQUIS (apixaban) This product information is intended only for residents of the United States. for Healthcare professionals: Visit www.eliquis.com for U.S. Physician Prescribing Information
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Find savings options for eligible patients with AFib not caused by a heart valve problem or with DVT/PE, such as the Rx ELIQUIS® copay card. See BOXED WARNINGS.
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Includes Eliquis side effects, interactions and indications.
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with ...
Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and MEDICATION GUIDE. ELIQUIS is available in 2.5 mg and 5 mg tablets. See Indications and Important Safety Information, including Boxed WARNINGS. Find dosing and administration information to prescribe ELIQUIS® to patients.
Generic Name: apixaban. Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/ knee replacement surgery. With...
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). ELIQUIS is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial therapy.